Radiation Therapy Approaches for People With Prostate Cancer

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase: Enrolling; Phase 2

Conditions: Non-metastatic Prostate Cancer; High Risk Prostate Cancer; Prostate Cancer Patients

Treatments: Radiation: Brachytherapy; Drug: SBRT

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07751159

26-288

Details and patient eligibility

About

The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.

Enrollment: 126 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Non-metastatic prostate cancer.
• Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed)
• Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT (see clinical considerations for treatment eligibility below)

Exclusion criteria

• None

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

126 participants in 2 patient groups

Arm A: HDR Brachytherapy Boost + SBRT

Active Comparator group

Description:

Standard of Care Brachytherapy/Radiation and SBRT

Treatment:

Radiation: Brachytherapy

Drug: SBRT

Arm B: SBRT Alone

Experimental group

Description:

SBRT alone

Treatment:

Drug: SBRT